Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | Unit 1 Masons Press, 7 Ravenscraig Road, CAPE TOWN 7925 |
Tel: | N/A |
Website: | https://m2bio.co |
IR: | See website |
Key People | ||
Jeffrey Robinson Chief Executive Officer | Anna Leralta Morera Secretary and Chief Medical Officer, Director | Luka Marjanovic Director of Human Resources and Communications |
Selah Abrams Director of Corporate Strategic Partnerships | Rameez Adair Director of Social Media | Riyad Domingo Chief Innovation Officer |
Willem Jonker Chief Operating Officer - Cannabis Cultivation Project | Ramy Kamaneh Consultant | Johann McLoughlin Director of Product Development and Visual Communications and Design | Robert Simbowe Director of Health and Fitness |
Business Overview |
Wuhan General Group (China) Inc is a South Africa-based bioceutical company. The Company is focused on alternative plant-based cannabinoids and mental health therapeutic research. Through its subsidiary, Neur.ai, the Company is engaged in developing a portfolio of receptor agonists based on neurotransformational medicine for the treatment of mental illness. The Company develops and commercializes a range of cannabidiol (CBD) and mushrooms-based products under the Dr. AnnaRx, Medspresso, and Liviana brands. The brands span across a range of premium CBD- and mushroom-infused consumer goods, including bioceuticals, health and wellness, and precision foods and beverages. In addition, the Company's research and clinical trials with psilocybin are aimed at new therapies that seek to help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Its Liviana brand offers CBD-infused raw honey and CBD-infused extra virgin olive oils. |
Financial Overview |
For the fiscal year ended 31 December 2012, Wuhan General Group (China) Inc revenues decreased 37% to $80.4M. Net loss applicable to common stockholders excluding extraordinary items increased from $3.7M to $10.6M. Revenues reflect Wuhan Generating Equipment segment decrease of 42% to $35.3M, Wuhan Blower segment decrease of 33% to $45.1M. Higher net loss reflects Interest Expense increase of 33% to $10.2M (expense). |